CD33
Cross-source consensus on CD33 from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Benefits
Risks & contraindications
Where it comes from
Highlighted claims
- CD33 is expressed on most AML cells and also on normal myeloid cells and progenitors. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- CD33 is therapeutically attractive but difficult to target because CD33-directed treatments can injure normal hematopoiesis. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- After transplant, the myeloid population lacked CD33 surface protein. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- CD33 was considered suitable for deletion because it is hematopoietic-restricted, common in AML, and appears dispensable for hematopoiesis. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- GO treatment increased the proportion of CD33-negative cells in peripheral blood after the first cycle and maintained near-complete CD33 negativity later. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
- The study supports the concept that CD33 can be removed from donor hematopoiesis to make it a more leukemia-selective target after transplant. — CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial